Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 185

1.

Treatment strategies aiming at remission in early rheumatoid arthritis patients: starting with methotrexate monotherapy is cost-effective.

Schipper LG, Kievit W, den Broeder AA, van der Laar MA, Adang EM, Fransen J, van Riel PL.

Rheumatology (Oxford). 2011 Jul;50(7):1320-30. doi: 10.1093/rheumatology/ker084. Epub 2011 Mar 2.

PMID:
21371999
[PubMed - indexed for MEDLINE]
Free Article
2.

Cost utility of tumour necrosis factor-α inhibitors for rheumatoid arthritis: an application of Bayesian methods for evidence synthesis in a Markov model.

Nguyen CM, Bounthavong M, Mendes MA, Christopher ML, Tran JN, Kazerooni R, Morreale AP.

Pharmacoeconomics. 2012 Jul 1;30(7):575-93. doi: 10.2165/11594990-000000000-00000. Review. Erratum in: Pharmacoeconomics. 2012 Nov 1;30(11):1096.

PMID:
22640174
[PubMed - indexed for MEDLINE]
3.

[Contribution of leflunomide to the cost effectiveness of sequential DMARD therapy of rheumatoid arthritis in Germany].

Schädlich PK, Zeidler H, Zink A, Gromnica-Ihle E, Schneider M, Straub C, Brecht JG, Huppertz E.

Z Rheumatol. 2004 Feb;63(1):59-75. German.

PMID:
14991279
[PubMed - indexed for MEDLINE]
4.

Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry.

Brennan A, Bansback N, Nixon R, Madan J, Harrison M, Watson K, Symmons D.

Rheumatology (Oxford). 2007 Aug;46(8):1345-54. Epub 2007 Jun 11.

PMID:
17562686
[PubMed - indexed for MEDLINE]
Free Article
5.

Modeling the 5-year cost effectiveness of treatment strategies including tumor necrosis factor-blocking agents and leflunomide for treating rheumatoid arthritis in the Netherlands.

Welsing PM, Severens JL, Hartman M, van Riel PL, Laan RF.

Arthritis Rheum. 2004 Dec 15;51(6):964-73.

PMID:
15593319
[PubMed - indexed for MEDLINE]
Free Article
6.

Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial.

Kobelt G, Lindgren P, Singh A, Klareskog L.

Ann Rheum Dis. 2005 Aug;64(8):1174-9. Epub 2005 Feb 11.

PMID:
15708879
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

[Health-economic assessment of combination therapy for rheumatoid arthritis with methotrexat and etanercept based on the TEMPO Study].

Schulze-Koops H, Deeg M, Runge C, Volmer T, Brecht JG.

Z Rheumatol. 2009 Dec;68(10):836-41. doi: 10.1007/s00393-009-0506-7. German.

PMID:
19756664
[PubMed - indexed for MEDLINE]
8.

Cost-effectiveness of sequential therapy with tumor necrosis factor antagonists in early rheumatoid arthritis.

Davies A, Cifaldi MA, Segurado OG, Weisman MH.

J Rheumatol. 2009 Jan;36(1):16-26. doi: 10.3899/jrheum.080257.

PMID:
19012363
[PubMed - indexed for MEDLINE]
9.

Modeling and cost-effectiveness analysis of etanercept in adults with rheumatoid arthritis in Japan: a preliminary analysis.

Tanno M, Nakamura I, Ito K, Tanaka H, Ohta H, Kobayashi M, Tachihara A, Nagashima M, Yoshino S, Nakajima A.

Mod Rheumatol. 2006;16(2):77-84.

PMID:
16633926
[PubMed - indexed for MEDLINE]
10.

Cost effectiveness of tumour necrosis factor-alpha inhibitors as first-line agents in rheumatoid arthritis.

Spalding JR, Hay J.

Pharmacoeconomics. 2006;24(12):1221-32.

PMID:
17129076
[PubMed - indexed for MEDLINE]
11.

A cost effectiveness analysis of treatment options for methotrexate-naive rheumatoid arthritis.

Choi HK, Seeger JD, Kuntz KM.

J Rheumatol. 2002 Jun;29(6):1156-65.

PMID:
12064828
[PubMed - indexed for MEDLINE]
12.

Preliminary evaluation in rheumatoid arthritis activity in patients treated with TNF-alpha blocker plus methotrexate versus methotrexate or leflunomide alone.

Wisłowska M, Jakubicz D.

Rheumatol Int. 2007 May;27(7):641-7. Epub 2007 Jan 18.

PMID:
17235556
[PubMed - indexed for MEDLINE]
13.

Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate.

Vera-Llonch M, Massarotti E, Wolfe F, Shadick N, Westhovens R, Sofrygin O, Maclean R, Yuan Y, Oster G.

Rheumatology (Oxford). 2008 Apr;47(4):535-41. doi: 10.1093/rheumatology/ken007.

PMID:
18356179
[PubMed - indexed for MEDLINE]
Free Article
14.

Drug survival, efficacy and toxicity of monotherapy with a fully human anti-tumour necrosis factor-alpha antibody compared with methotrexate in long-standing rheumatoid arthritis.

Barrera P, van der Maas A, van Ede AE, Kiemeney BA, Laan RF, van de Putte LB, van Riel PL.

Rheumatology (Oxford). 2002 Apr;41(4):430-9.

PMID:
11961174
[PubMed - indexed for MEDLINE]
Free Article
15.

The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population-based study.

Finckh A, Dehler S, Gabay C; SCQM doctors.

Ann Rheum Dis. 2009 Jan;68(1):33-9. doi: 10.1136/ard.2007.085696. Epub 2008 Jan 29.

PMID:
18230627
[PubMed - indexed for MEDLINE]
16.

Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis.

Finckh A, Bansback N, Marra CA, Anis AH, Michaud K, Lubin S, White M, Sizto S, Liang MH.

Ann Intern Med. 2009 Nov 3;151(9):612-21. doi: 10.7326/0003-4819-151-9-200911030-00006.

PMID:
19884622
[PubMed - indexed for MEDLINE]
17.

The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study.

Kobelt G, Jönsson L, Young A, Eberhardt K.

Rheumatology (Oxford). 2003 Feb;42(2):326-35.

PMID:
12595631
[PubMed - indexed for MEDLINE]
Free Article
18.

Assessing the cost-effectiveness of biologic agents for the management of moderate-to-severe rheumatoid arthritis in anti-TNF inadequate responders in Italy: a modelling approach.

Cimmino MA, Leardini G, Salaffi F, Intorcia M, Bellatreccia A, Dupont D, Beresniak A.

Clin Exp Rheumatol. 2011 Jul-Aug;29(4):633-41. Epub 2011 Aug 31.

PMID:
21813056
[PubMed - indexed for MEDLINE]
19.

Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis.

Wong JB, Singh G, Kavanaugh A.

Am J Med. 2002 Oct 1;113(5):400-8.

PMID:
12401535
[PubMed - indexed for MEDLINE]
20.

Infliximab: a pharmacoeconomic review of its use in rheumatoid arthritis.

Lyseng-Williamson KA, Foster RH.

Pharmacoeconomics. 2004;22(2):107-32. Review.

PMID:
14731052
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk